Brind.

Janssen received EC approval for DARZALEX Faspro co-formulated with ENHANZE.

1 report, 1 independent Updated Jul 23

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Janssen Halozyme Therapeutics Johnson & Johnson

Keep exploring

The entities involved

Janssen
company in Cologno Monzese, Italy

Nothing else this week.
Halozyme Therapeutics
Nothing else this week.
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04

Related events

GSK, Incyte, Vertex, and Janssen announced new collaboration agreements with Halozyme on September 21, 2026.Sep 22

Coverage

Newest first; wire copies grouped

Jul 23PR NewswireEuropean Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represe